5-Amino-4-Imidazole Carboxamide Ribosiduria (AICA-Ribosiduria)

5-amino-4-imidazole carboxamide ribosiduria is an ultra-rare, inherited metabolic disease that affects how the body makes purines, the building blocks of DNA, RNA, and energy molecules. The problem comes from harmful changes (mutations) in the ATIC gene, which makes a two-in-one enzyme needed for the last two steps of de novo purine synthesis. When this enzyme does not work well, a substance called AICA-riboside (AICAr) and its related compounds build up and spill into the urine and body tissues. This can disturb brain and eye development and can cause severe developmental delay, seizures, and serious vision problems in many patients. The condition is autosomal recessive, meaning both gene copies must be faulty. PMCPubMedWiley Online LibraryOrpha

AICA-ribosiduria is a very rare, inherited problem in the body’s purine factory (purines are building blocks for DNA, RNA, and energy molecules). A single enzyme, called ATIC, normally completes the last two steps of purine making. When ATIC does not work, a chemical called AICA-riboside (AICAr) builds up in the body and spills into urine. Because purines are vital for the brain’s growth and function, babies and children with this condition usually have serious brain-related symptoms such as developmental delay, seizures, vision problems, and muscle weakness. The condition is autosomal recessive (both parents carry one non-working gene), and worldwide only a handful of patients have ever been reported, so knowledge is limited and care is focused on supportive treatment, safety, and quality of life. OrphaWiley Online Librarygenome.jp

---

Other names

This disorder is also called AICA-ribosiduria, 5-amino-4-imidazolecarboxamide ribosiduria, ATIC deficiency, AICAR transformylase/IMP cyclohydrolase deficiency, bifunctional PURH (ATIC) deficiency, and in some catalogs AICA-ribosiduria due to ATIC deficiency (MIM 608688). All these names refer to the same problem: a deficiency of the ATIC enzyme that performs the final two steps of purine synthesis, leading to accumulation and urinary excretion of AICA-riboside. Global Genesgenome.jp

---

Types

Because this disease is so rare, doctors describe types by severity rather than strict subtypes:

1. Classic severe form. Marked developmental delay, early-onset seizures, severe visual impairment (often from chorioretinal atrophy), growth issues, scoliosis, and typical facial features. This was the profile of the earliest reported patient. PubMedPMC

2. Milder/attenuated form. More recent reports show siblings with a milder neurologic picture, expanding the spectrum and indicating that severity can vary with different ATIC variants. PubMedWiley Online Library

3. Intermediate presentations. Case series that gathered several patients suggest intermediate severity between these two ends may also occur. Wiley Online Library

---

Causes

Although this is a genetic disease with one primary cause (faulty ATIC), it helps to explain the many ways that single cause creates problems in the body. Items 1–7 are the core, proven causes; items 8–20 describe well-accepted downstream effects or modifiers that make symptoms worse.

1. Biallelic ATIC gene mutations. Both copies of the ATIC gene carry harmful changes, so the enzyme cannot work normally. PubMed

2. Loss of AICAR transformylase activity. The “first half” of the enzyme is often most affected, blocking the step that adds a formyl group to AICAR. PMC

3. Partial loss of IMP cyclohydrolase activity. The “second half” may still have some function but is usually reduced. PMC

4. Build-up of AICA-riboside (AICAr). The blocked pathway leads to accumulation and urinary excretion of AICAr—the biochemical hallmark. Wiley Online LibraryOrpha

5. Shortage of new purines (IMP). With the last steps blocked, the body cannot produce enough IMP, the branch point for adenine and guanine nucleotides. (Mechanism follows from the known role of ATIC in the de novo pathway.) genome.jp

6. Reduced ATP/GTP availability in developing brain. Low purine supply can limit energy and RNA/DNA building needs during brain development. (Inference from pathway disruption.) genome.jp

7. Toxic effects of accumulated intermediates. High levels of AICAr/AICAR-related metabolites may disturb normal cell signaling and metabolism. (Supported by metabolite accumulation findings.) PMC

8. Neuronal network development disturbance. Inadequate purines during critical windows can impair synapse formation and myelination, contributing to developmental delay. (Pathway-based rationale.)

9. Retinal/chorio-retinal vulnerability. The retina has high metabolic demand; purine shortage and metabolite build-up likely underlie severe visual loss found in cases. Wiley Online Library

10. Epileptogenic tendency. Metabolic stress and neurotransmission imbalance raise seizure risk, commonly reported. PubMed

11. Growth impairment. Systemic metabolic insufficiency can impair growth pre- and post-natally. Global Genes

12. Scoliosis development. Neuromuscular imbalance and connective tissue factors may contribute to scoliosis in childhood. Global Genes

13. Dysmorphic features. Abnormal facial features likely reflect early developmental effects of purine imbalance. GeneCards

14. Cardiac defects (some patients). Rarely, congenital heart disease is reported. Metabolic Support UK

15. Liver involvement (some patients). Hepatomegaly or fatty change has been described in a minority. Metabolic Support UK

16. Visual pathway dysfunction. Beyond retinal disease, visual evoked responses may be abnormal, reducing visual function.

17. Muscle hypotonia. Low tone is frequent in children with global developmental delay in metabolic disorders.

18. Feeding difficulties and failure to thrive. Poor coordination and high metabolic needs can impair weight gain.

19. Genetic risk from consanguinity. When both parents share ancestry, the chance of two faulty copies is higher in autosomal recessive conditions. (General genetic principle.)

20. Illness or fasting as stressors. Intercurrent illness may temporarily worsen neurological symptoms in metabolic diseases (general principle for inborn errors).

(Where I cite general principles, these are standard genetics/metabolism concepts; the core, referenced causes are 1–7 and the specific clinical associations above.)

---

Symptoms

1. Global developmental delay. Children reach milestones late: sitting, standing, speaking, learning. This is the most consistent feature. PubMedWiley Online Library

2. Intellectual disability. Learning problems can be severe, and often persist into later life. GeneCards

3. Seizures/epilepsy. Fits may start early in life and can be hard to control in some patients. PubMed

4. Severe visual impairment. Many patients have very poor vision due to chorioretinal atrophy or other retinal problems; some are blind. Wiley Online Library

5. Eye structure/retina changes. Eye doctors may see retinal thinning or scarring on exam. Wiley Online Library

6. Hypotonia (low muscle tone). Babies feel “floppy,” and older children may have weak posture control.

7. Scoliosis. The spine curves sideways during growth. Global Genes

8. Growth restriction. Poor weight gain or short stature can occur before and after birth. Global Genes

9. Distinct facial features. An upturned nose, bushy eyebrows, long eyelashes, and dimples over joints were described in some patients. Metabolic Support UK

10. Feeding difficulties. Suck-swallow problems in infancy or poor chewing in childhood can happen.

11. Behavioral challenges. Irritability, attention problems, or stereotypies may appear with neurodevelopmental disorders.

12. Sleep problems. Fragmented sleep can worsen daytime functioning.

13. Motor delay. Late walking, clumsy gait, or poor fine motor skills.

14. Speech and language delay. First words and phrases come late; speech may remain limited.

15. Occasional heart or liver issues. A few patients have congenital heart disease or liver enlargement/fatty liver. Metabolic Support UK

---

Diagnostic tests

A) Physical examination (bedside)

1. General growth check (height/weight/head size). Looks for growth restriction or microcephaly that fits a metabolic cause; done at every visit.

2. Neurological exam. Assesses tone, reflexes, coordination, and seizure signs to map the developmental profile.

3. Spine inspection for scoliosis. Adam’s forward bend test and posture checks detect early curvature. Global Genes

4. Vision and eye alignment screen. Bedside fixation on lights, pupillary responses, and tracking to spot early visual loss.

5. Dysmorphology review. Notes features (upturned nose, bushy eyebrows, long eyelashes) and joint dimples that can hint at this diagnosis. Metabolic Support UK

B) Manual/functional assessments

6. Standardized developmental scales. Tools like Bayley or Griffiths quantify motor, language, and cognitive skills to document delay.

7. Detailed ophthalmologic examination. Slit-lamp and dilated fundus exam by an eye specialist look for chorioretinal atrophy and other retinal changes tied to vision loss. Wiley Online Library

8. Nutritional and feeding evaluation. Structured feeding assessments identify swallowing issues or calorie deficits contributing to failure to thrive.

C) Laboratory and pathological tests

9. Urine purine metabolite profile (LC-MS/MS). The key test: detects high AICA-riboside (AICAr) excretion—the biochemical hallmark. Diagnostic labs use mass spectrometry or capillary electrophoresis. ScienceDirectWiley Online Library

10. Erythrocyte/fibroblast metabolite analysis. Shows accumulation of AICAR/ZMP inside cells, supporting the block in the pathway. PMC

11. Targeted ATIC gene sequencing. Confirms biallelic pathogenic variants (missense, nonsense, frameshift, splice). This is the definitive diagnosis. PubMed

12. Broad exome/genome sequencing. Used when the diagnosis is unclear; can find ATIC variants in undiagnosed patients.

13. Enzyme activity studies (research/rarely clinical). Measures AICAR transformylase and IMP cyclohydrolase activity in patient cells; classic reports showed profound transformylase deficiency. PMC

14. Basic metabolic panel and liver tests. Rules out other causes of developmental delay and checks for occasional liver involvement. Metabolic Support UK

D) Electrodiagnostic tests

15. EEG (electroencephalogram). Looks for seizure activity and helps guide anti-seizure treatment in affected children. (Seizures are common.) PubMed

16. Visual evoked potentials (VEP). Measures the brain’s electrical response to visual stimuli and can show pathway dysfunction beyond what the eye exam reveals.

17. Electroretinography (ERG). Tests retinal function; reduced signals fit chorioretinal disease and severe visual loss.

E) Imaging tests

18. Brain MRI. Assesses structural brain changes associated with metabolic disorders and explains neurologic signs.

19. Spine X-ray or EOS scan. Documents degree of scoliosis for monitoring or bracing decisions. Global Genes

20. Ocular imaging (OCT/fundus photography). Shows retinal thinning or atrophy that aligns with poor vision and supports the diagnosis. Wiley Online Library

Non-pharmacological treatments

Physiotherapy

1. Early developmental physiotherapy
   Description (≈150 words): Start as early as possible with gentle, play-based movement sessions led by a pediatric physiotherapist. Sessions focus on head control, rolling, sitting balance, reaching, and transitional movements (sit-to-stand). Use soft positioning aids, floor time, and short, frequent practice to prevent fatigue. Parents learn home routines: 10–15 minutes, 3–5 times daily.
   Purpose: Build motor milestones; reduce delay.
   Mechanism: Repeated task practice strengthens neuromotor pathways, improves tone control, and protects joints.
   Benefits: Better posture, easier caregiving, fewer contractures, improved comfort and participation.

2. Tone management program
   Description: Individualized stretching, weight-bearing, and positioning to manage hypotonia or mixed tone. Includes supported standing frames and ankle-foot orthoses (AFOs) if needed.
   Purpose: Maintain muscle length and joint range.
   Mechanism: Regular stretch and controlled load counteract contracture and deformity.
   Benefits: Less stiffness, better comfort, easier transfers.

3. Postural care & 24-hour positioning
   Description: Day and night positioning plan (seating, lying, standing) to protect spine and hips. Custom seating with lateral supports and pelvic straps if needed.
   Purpose: Prevent scoliosis/hip subluxation; improve breathing and feeding alignment.
   Mechanism: Symmetrical support reduces abnormal forces on the spine/hips.
   Benefits: Lower pain, easier care, better respiratory function.

4. Supported standing program
   Description: Standing frame use 30–60 minutes/day, 5–7 days/week, as tolerated.
   Purpose: Bone health, hip stability, circulation, and bowel function.
   Mechanism: Axial loading stimulates bone and joint development.
   Benefits: Less osteoporosis risk; improved digestion and alertness.

5. Gait training (with or without device)
   Description: Treadmill with body-weight support, parallel bars, or walker practice.
   Purpose: Improve ambulation potential and endurance.
   Mechanism: Repetitive stepping strengthens locomotor circuits.
   Benefits: Greater mobility or safer assisted transfers.

6. Respiratory physiotherapy
   Description: Chest physiotherapy, supported coughing, and breathing games; teach parents airway clearance during colds.
   Purpose: Reduce chest infections.
   Mechanism: Improves ventilation and mucus clearance.
   Benefits: Fewer hospital visits, better energy.

7. Oro-motor therapy
   Description: Work on jaw stability, lip seal, tongue movement; safe swallowing postures and pacing; nipple or utensil adaptations.
   Purpose: Safer feeding.
   Mechanism: Strengthens coordination of suck-swallow-breathe.
   Benefits: Reduced choking/aspiration; better growth.

8. Constraint-induced movement therapy (CIMT) (modified)
   Description: Brief, playful activities that encourage use of the weaker side while gently limiting the stronger side for minutes at a time.
   Purpose: Improve bilateral hand use.
   Mechanism: Drives cortical re-organization through use-dependent plasticity.
   Benefits: More functional reach/grasp in daily life.

9. Task-specific hand function training
   Description: Reaching, gripping, releasing, stacking blocks, and turn-taking games.
   Purpose: Practical hand skills.
   Mechanism: Motor learning principles (repetition, feedback).
   Benefits: Better self-care and play.

10. Hydrotherapy
    Description: Warm-water sessions for relaxed movement; buoyancy reduces effort, allowing practice of patterns hard on land.
    Purpose: Increase range and reduce pain.
    Mechanism: Water supports weight and provides gentle resistance.
    Benefits: Enjoyment, sleep, and mood often improve.

11. Pain prevention & gentle manual therapy
    Description: Soft tissue work and joint mobilization within comfort; avoid aggressive manipulation.
    Purpose: Reduce discomfort from stiffness or deformity.
    Mechanism: Improves circulation and reduces guarding.
    Benefits: Better tolerance for daily care.

12. Hip surveillance protocol
    Description: Regular clinical checks and periodic pelvic x-rays guided by orthopedic/physio team.
    Purpose: Early detection of hip migration.
    Mechanism: Monitoring prompts timely bracing or surgical referral.
    Benefits: Prevents severe deformity and pain.

13. Assistive technology & seating systems
    Description: Custom seating, standing frames, walkers, adaptive switches, and simple communication access.
    Purpose: Posture, function, and participation.
    Mechanism: Right equipment reduces energy cost and strain.
    Benefits: Independence and caregiver ease.

14. Home exercise program (HEP) coaching
    Description: Short, repeatable routines with clear goals; video reminders for families.
    Purpose: Continuity between visits.
    Mechanism: Frequent practice beats occasional long sessions.
    Benefits: Faster functional gains.

15. Falls-prevention and safe-handling training
    Description: Environmental setup, transfer techniques, and caregiver body mechanics.
    Purpose: Safety for child and caregivers.
    Mechanism: Reduces risky leverage and slips.
    Benefits: Fewer injuries and hospital visits.

Mind-Body, Education, and Care Training

16. Caregiver education “toolbox”
    Description (≈150 words): Step-by-step guides for feeding, positioning, seizure first aid, medication schedules, and warning signs. Printed “go-bag” sheet for emergencies.
    Purpose: Reduce anxiety; standardize safe care.
    Mechanism: Knowledge + checklists lower errors.
    Benefits: Safer home care and quicker help when needed.

17. Seizure action plan & first-aid training
    Purpose: Rapid, calm response; when to give rescue meds; when to call EMS.
    Mechanism: Preparedness reduces harm.
    Benefits: Fewer complications.

18. Sleep hygiene coaching
    Purpose: Better sleep improves daytime learning and seizure threshold.
    Mechanism: Consistent routines, light control, and calming practice.
    Benefits: Child and caregiver rest.

19. Feeding and nutrition counseling
    Purpose: Adequate calories, safe textures; consider ketogenic or lower-glycemic diet if epilepsy is refractory (medical supervision required).
    Mechanism: Tailored macros and texture reduce aspiration and support growth.
    Benefits: Weight gain, fewer hospitalizations.

20. Augmentative & alternative communication (AAC)
    Purpose: Give a voice: pictures, signs, eye-gaze, or simple speech devices.
    Mechanism: Low-tech to high-tech supports reduce frustration.
    Benefits: Better behavior and connection.

21. Behavioral therapy (parent-mediated)
    Purpose: Manage irritability, sensory overload, sleep resistance.
    Mechanism: Positive routines and antecedent management.
    Benefits: Calmer days, easier therapies.

22. Psychological support for family
    Purpose: Reduce caregiver burnout; address grief and stress.
    Mechanism: Counseling and peer groups.
    Benefits: Resilience and better long-term care.

23. Educational therapy & individualized education plan (IEP)
    Purpose: Access to special education, therapy minutes at school, and accommodations.
    Mechanism: Goals in communication, mobility, and self-care.
    Benefits: Skill development and inclusion.

24. Vision support
    Purpose: Optimize remaining vision and access.
    Mechanism: Low-vision aids, contrast, lighting, and orientation-mobility training.
    Benefits: Independence and safety.

25. Ethics & advanced-care planning
    Purpose: Align care with family values; anticipate critical decisions.
    Mechanism: Structured conversations with palliative team.
    Benefits: Clear goals; less crisis decision-making.

Why emphasize non-drug care? Because there is no proven curative therapy yet; supportive, team-based care is the foundation and is evidence-aligned for rare neurometabolic diseases. Global Genes

---

Drug treatments

(Each in ~150-word style with class, common dosing ranges for pediatrics/adults where standard, timing, purpose, mechanism, and key side effects. Doses must be individualized by the treating clinician.)

1. Levetiracetam (antiepileptic; SV2A modulator)
   Dose: Common pediatric start 10–20 mg/kg/day divided BID; titrate per response.
   Time: BID.
   Purpose: Control focal/generalized seizures.
   Mechanism: Modulates synaptic vesicle protein to stabilize neuronal firing.
   Side effects: Irritability, somnolence; rarely mood changes.
   Why here: Often first-line in complex neurodevelopmental epilepsies.

2. Valproate (broad-spectrum antiepileptic)
   Dose: 10–15 mg/kg/day, titrate; monitor troughs and liver function.
   Time: BID–TID.
   Purpose: Mixed seizure types including myoclonic/generalized.
   Mechanism: Increases GABA; sodium channel effects.
   Side effects: Weight gain, tremor, liver toxicity, thrombocytopenia; teratogenic—avoid in pregnancy.

3. Lamotrigine (antiepileptic; Na⁺ channel modulator)
   Dose: Slow titration to reduce rash risk; typical 1–5 mg/kg/day target (varies).
   Purpose: Adjunct or primary therapy for focal/generalized seizures.
   Side effects: Rash (rare SJS), dizziness, insomnia.

4. Topiramate
   Dose: 1–9 mg/kg/day divided; gradual titration.
   Purpose: Adjunct for refractory epilepsy; sometimes helpful with migraine.
   Side effects: Appetite loss, acidosis, kidney stones, cognitive slowing.

5. Clobazam (benzodiazepine)
   Dose: 0.25–1 mg/kg/day divided.
   Purpose: Add-on for refractory seizures.
   Side effects: Sedation, tolerance, constipation.

6. Midazolam rescue (buccal/intranasal)
   Dose: Per local protocol for seizures >5 min or clusters.
   Purpose: Home/emergency seizure stop.
   Side effects: Sedation, respiratory depression (monitor).

7. Baclofen (GABA-B agonist for spasticity)
   Dose: 0.3–0.75 mg/kg/day divided; titrate.
   Purpose: Reduce painful spasms and improve care.
   Side effects: Sedation, weakness; taper slowly.

8. Tizanidine (α2-agonist)
   Dose: Start low; titrate.
   Purpose: Alternative/adjunct to baclofen for tone.
   Side effects: Sleepiness, hypotension, LFT elevation.

9. Melatonin
   Dose: 1–5 mg at bedtime (peds typical start 1–3 mg).
   Purpose: Sleep onset/maintenance.
   Side effects: Morning grogginess; interacts with some meds.

10. Proton-pump inhibitor (e.g., omeprazole)
    Dose: Pediatric/weight-based.
    Purpose: GERD symptoms, reduce aspiration risk.
    Side effects: Diarrhea, low magnesium with long term.

11. Polyethylene glycol (PEG)
    Dose: Titrate to one soft stool/day.
    Purpose: Constipation from immobility/meds.
    Side effects: Bloating.

12. Vitamin D3 (cholecalciferol)
    Dose: Per levels (e.g., 600–1000 IU/day typical maintenance).
    Purpose: Bone health with immobility/antiepileptics.
    Side effects: Rare hypercalcemia—monitor.

13. Multivitamin with folate
    Purpose: General micronutrient sufficiency; avoid folate deficiency (ATIC is folate-linked enzyme).
    Note: Avoid antifolate drugs (e.g., high-dose methotrexate) unless medically necessary.
    Side effects: Usually minimal; check interactions. PMC

14. Carbidopa-levodopa (selected cases)
    Purpose: If dystonia/parkinsonian features present; trial by specialist.
    Side effects: Nausea, dyskinesia; careful titration.

15. Ketogenic diet as “metabolic therapy” (medical nutrition but prescribed like a drug)
    Purpose: Refractory epilepsy control; sometimes improves alertness.
    Mechanism: Ketosis alters brain energy use and excitability.
    Risks: Hypoglycemia, acidosis, kidney stones—must be dietitian-supervised.

Important: No medicine is currently proven to “fix” the enzyme defect in people. Drug choices are about symptom control and safety, guided by your neurology/metabolic team. Research into pathway suppression and purine supplementation is ongoing. ScienceDirectClinicalTrials.gov

---

Dietary molecular supplements

(These do not cure the disorder; they support general brain/nerve health or seizure care. Always discuss with your clinician.)

1. Omega-3 fatty acids (EPA/DHA) — 250–500 mg/day combined (child dosing by weight). Function: anti-inflammatory, neuronal membrane support. Mechanism: membrane fluidity, signaling.

2. MCT oil — dose titrated by dietitian, especially with ketogenic plans. Function: alternative brain fuel (ketones). Mechanism: rapid hepatic ketogenesis.

3. Creatine monohydrate — 0.1 g/kg/day. Function: cellular energy buffer. Mechanism: phosphocreatine shuttle.

4. Coenzyme Q10 (ubiquinone) — 2–5 mg/kg/day. Function: mitochondrial electron transport.

5. L-carnitine — per weight; helpful if on valproate or ketogenic diet. Function: fatty acid transport.

6. Magnesium — per age; may aid sleep and migraine-like symptoms. Function: NMDA modulation.

7. Riboflavin (B2) — supports mitochondrial enzymes.

8. Pyridoxine (B6) — only under guidance; some epilepsies respond.

9. Choline — membrane and neurotransmitter precursor.

10. Vitamin D — as above; bone/immune support.

Note: Strong human data specific to ATIC deficiency are lacking; use is adjunctive and individualized.

---

Immunity-booster / regenerative / stem-cell” drugs

(There is no approved disease-modifying biologic. The items below describe conceptual or experimental directions so families know what researchers are exploring. They are not clinical recommendations.)

1. AAV-based gene augmentation of ATIC
   Dose/route: Future investigational IV/CSF vectors. Function: Provide working ATIC gene. Mechanism: Viral vector adds functional copy to neurons/glia. Status: Pre-clinical concept.

2. mRNA therapy for ATIC
   Function: Deliver ATIC mRNA to cells for transient enzyme replacement. Mechanism: LNP-encapsulated mRNA translation. Status: Experimental platform in other diseases.

3. CRISPR base-editing of ATIC variants
   Function: Correct pathogenic point variants in situ. Mechanism: Guide-directed base editors. Status: Laboratory stage.

4. Substrate reduction / pathway suppression
   Function: Partially slow upstream purine synthesis to reduce toxic metabolite buildup (carefully balanced). Mechanism: Target enzymes or folate-dependent steps. Status: Research reports suggest feasibility in models/patients under study; clinical protocols are investigational. ScienceDirect

5. Purine supplementation strategies
   Function: Provide salvageable purines to support cells. Mechanism: Increase availability via salvage pathways. Status: Clinical trial activity exists; outcomes pending. ClinicalTrials.gov

6. Neurotrophic biologics (e.g., IGF-1 pathway modulators)
   Function: Promote neuronal survival/synapse health. Mechanism: Trophic signaling. Status: General neurodevelopmental research—not ATIC-specific.

---

Surgeries (why they’re done)

1. Vagus nerve stimulator (VNS) implantation
   Why: For drug-resistant epilepsy to reduce seizure frequency.

2. Spinal fusion for severe scoliosis
   Why: Prevent progression that impairs breathing/sitting; relieve pain.

3. Gastrostomy tube (G-tube)
   Why: Severe feeding/swallowing problems; secure nutrition and meds; reduce aspiration.

4. Orthopedic soft-tissue lengthening (e.g., Achilles)
   Why: Fixed contractures causing pain, hygiene problems, or bracing limits.

5. Strabismus surgery / cataract management (case-by-case)
   Why: Optimize vision alignment or treat lens opacity to improve access and comfort.

---

Prevention & safety strategies

1. Genetic counseling for parents/siblings; discuss carrier testing and future pregnancy options.

2. Vaccinations per schedule to reduce infection-triggered regressions.

3. Seizure safety plan at home and school; rescue medication training.

4. Avoid prolonged fasting and dehydration; maintain steady energy intake.

5. Medication review to avoid antifolate exposures (e.g., high-dose methotrexate/trimethoprim) unless absolutely necessary. PMC

6. Hip/spine surveillance to catch deformities early.

7. Swallow safety: texture modification and aspiration precautions.

8. Skin integrity: pressure-relief cushions and turning schedules.

9. Sleep hygiene to lower seizure risk and daytime fatigue.

10. Emergency information sheet with diagnosis, meds, and contacts.

---

When to see a doctor

• Right away / emergency: Seizure >5 minutes, repeated clusters, breathing trouble, blue lips, severe choking, unresponsiveness, high fever with lethargy, sudden weakness or new paralysis, severe vomiting with dehydration.

• Soon (within days): New or worse seizures, feeding decline/weight loss, repeated chest infections, increasing stiffness or pain, new curvature of the spine, persistent sleep problems, medication side effects (excessive sleepiness, liver concerns, rash), uncontrolled constipation, or caregiver burnout.

---

What to eat and what to avoid

1. Balanced, energy-dense meals to support growth; use dietitian plans.

2. Safe textures (pureed/soft) if swallowing risk; small, frequent feeds.

3. Consider ketogenic or modified Atkins only under neurology/dietitian supervision for refractory epilepsy.

4. Hydration: frequent fluids; oral rehydration during illness.

5. Protein with each meal to steady energy.

6. Fiber (fruit/veg/oats) plus PEG or stool plan to prevent constipation.

7. Omega-3-rich foods (fish, flax, chia) weekly.

8. Vitamin D/calcium sources (dairy/fortified) if not contraindicated.

9. Avoid antifolate drugs/supplements unless prescribed; always check new meds. PMC

10. Avoid choking hazards; follow swallow therapist guidance.

---

Frequently asked questions

1. Is AICA-ribosiduria the same as adenylosuccinate lyase (ADSL) deficiency?
   No. Both affect purine synthesis, but AICA-ribosiduria is due to ATIC defects; ADSL deficiency is a different enzyme problem with different metabolites (SAICAr and S-Ado). ScienceDirectMedlinePlus

2. How rare is it?
   Extremely rare—only a small number of patients have been reported worldwide so far. Wiley Online Library

3. What are the hallmark lab findings?
   Very high AICA-riboside in urine; elevated AICAR/ZMP in cells. Genetic testing confirms ATIC variants. PubMed

4. What symptoms are most common?
   Severe developmental delay, early seizures, visual impairment, growth issues, sometimes scoliosis. Global Genes

5. Is there a cure?
   No approved cure yet. Care focuses on seizures, nutrition, mobility, and communication.

6. Are there experimental treatments?
   Yes—research is exploring suppressing de novo purine synthesis and purine supplementation approaches, but these are investigational. ScienceDirectClinicalTrials.gov

7. Can diet help?
   Diet cannot fix the enzyme, but a ketogenic or related plan can help some patients with hard-to-control seizures (specialist supervision needed).

8. Will my child walk or talk?
   Abilities vary widely; many reported cases have severe impairment. Early therapies and assistive tech aim to maximize each child’s potential. Global Genes

9. Is it inherited?
   Yes, autosomal recessive—both parents are typically carriers. genome.jp

10. How is it different from “AICAR” used in labs/athletics stories?
    That AICAR is the same chemical name but supplement use is not appropriate here; in patients, excess AICAR is part of the disease.

11. Should we avoid certain medications?
    Discuss any antifolate medicines with your team, as ATIC is a folate-dependent enzyme. PMC

12. What specialists do we need?
    Metabolic/genetics, neurology, physiatry, physiotherapy/OT/SLP, dietetics, ophthalmology, orthopedics, palliative care.

13. Can siblings be tested?
    Yes. Carrier testing for relatives and prenatal options for future pregnancies are available through genetics clinics.

14. How do we track progress?
    Use a simple care plan with goals for mobility, feeding, sleep, seizures, and communication; adjust every 3–6 months.

15. Where can we find updated research or trials?
    Ask your metabolic clinic to monitor journals and ClinicalTrials.gov; rare disease organizations also post updates. ClinicalTrials.govGlobal Genes

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 10, 2025.